Management of Altered Mental Status After Haloperidol Administration

Initial Assessment and Treatment

The American College of Emergency Physicians recommends discontinuing haloperidol immediately and assessing for neuroleptic malignant syndrome in a patient with altered mental status after taking Haldol, and administering benzodiazepines (lorazepam 2-4 mg IV/IM) for symptom control while monitoring vital signs and cardiac status 1
Drug-induced delirium can occur in patients taking haloperidol, characterized by altered mental status, and should be considered in the differential diagnosis 2

Continuous cardiac monitoring is essential to assess the risk of QT prolongation and Torsades de pointes in patients taking haloperidol 1
Laboratory workup should include complete blood count, comprehensive metabolic panel, creatine kinase, ECG, and blood glucose to rule out underlying conditions such as leukopenia, electrolyte imbalances, rhabdomyolysis, and hypoglycemia 1

Lorazepam 2-4 mg IV/IM is recommended as first-line treatment for acute agitation, with an onset of action of 1-2 minutes IV, peak effect of 3-4 minutes, and duration of 15-80 minutes for sedative effects 1, 3, 4
For suspected neuroleptic malignant syndrome, aggressive cooling measures, IV fluids, and consideration of dantrolene or bromocriptine may be necessary 1

The following medications and dosages are recommended for acute agitation:

Medication	Dosage	Onset of Action	Duration of Action
Lorazepam	2-4 mg IM		217 minutes to arousal
Droperidol	5 mg IM	rapid
Haloperidol	5-10 mg IM	28.3 minutes	126 minutes to arousal
Midazolam	5 mg IM	18.3 minutes	82 minutes to arousal
Haloperidol + Lorazepam	5-10 mg IM + 2 mg IM
Haloperidol + Promethazine	10 mg IM + 25-50 mg IM		96% of patients tranquil or asleep at 4 hours

Elderly patients are at higher risk for extrapyramidal symptoms, sedation, falls, QT prolongation, and anticholinergic effects, and may require dose reduction of benzodiazepines 1
Avoid using epinephrine in patients with haloperidol toxicity, as it may worsen hypotension, and instead use metaraminol, phenylephrine, or norepinephrine 1
Respiratory depression is a significant risk with both lorazepam and clonazepam, especially when combined with opioids, and dose adjustments are necessary in elderly patients and those with ASA physical status 3 or above, with the American Society of Anesthesiologists recommending a 20% or more dose reduction in these patients 3
The combination of benzodiazepines with other CNS depressants can have synergistic effects, and withdrawal risk is a concern, especially with clonazepam's longer half-life 3

Admission for observation is typically warranted, and consideration of ICU admission may be necessary if severe neuroleptic malignant syndrome is suspected, significant cardiac abnormalities are present, respiratory compromise exists, or severe electrolyte abnormalities are detected 1
Documentation of haloperidol adverse reaction in the medical record, consideration of alternative antipsychotics, and education of the patient and family about medication risks and warning signs are essential 1
For undifferentiated agitation requiring rapid control, Droperidol 5 mg IM or benzodiazepine (midazolam or lorazepam) or antipsychotic (haloperidol) as monotherapy is recommended, with a strength of evidence considered high 1
For agitation in known psychiatric illness, Antipsychotic monotherapy (haloperidol 5-10 mg IM) is a first choice option, with a strength of evidence considered moderate 1
For severe agitation not responding to initial treatment, combination therapy with Haloperidol 5-10 mg + Lorazepam 2 mg IM is recommended 1
For cooperative but agitated patients, an oral combination of benzodiazepine and antipsychotic is considered, with a strength of evidence considered low 1